| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Stroke Volume | 69 | 2019 | 2153 | 8.70 | Why? |
| Heart Failure | 102 | 2021 | 6638 | 8.10 | Why? |
| Tetrazoles | 25 | 2019 | 262 | 5.43 | Why? |
| Aminobutyrates | 23 | 2019 | 142 | 4.92 | Why? |
| Mineralocorticoid Receptor Antagonists | 15 | 2019 | 203 | 4.28 | Why? |
| Spironolactone | 11 | 2019 | 114 | 4.12 | Why? |
| Enalapril | 15 | 2019 | 54 | 3.69 | Why? |
| Neprilysin | 11 | 2019 | 112 | 3.49 | Why? |
| Valsartan | 23 | 2019 | 206 | 3.46 | Why? |
| Ventricular Function, Left | 16 | 2019 | 1555 | 2.97 | Why? |
| Angiotensin Receptor Antagonists | 31 | 2022 | 3892 | 2.53 | Why? |
| Natriuretic Peptide, Brain | 14 | 2021 | 1215 | 2.08 | Why? |
| Biphenyl Compounds | 25 | 2019 | 249 | 2.05 | Why? |
| Ventricular Remodeling | 6 | 2019 | 349 | 1.91 | Why? |
| Atherosclerosis | 7 | 2018 | 768 | 1.78 | Why? |
| Amyloid Neuropathies, Familial | 4 | 2019 | 77 | 1.78 | Why? |
| Benzimidazoles | 5 | 2019 | 275 | 1.77 | Why? |
| Peptide Fragments | 14 | 2021 | 2075 | 1.64 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 10 | 2019 | 520 | 1.60 | Why? |
| Prealbumin | 4 | 2019 | 203 | 1.49 | Why? |
| Natriuretic Peptides | 3 | 2019 | 66 | 1.45 | Why? |
| Dipeptides | 2 | 2019 | 106 | 1.41 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 21 | 2022 | 5277 | 1.32 | Why? |
| Endpoint Determination | 6 | 2020 | 344 | 1.30 | Why? |
| Cardiac Resynchronization Therapy | 8 | 2019 | 191 | 1.20 | Why? |
| Heart Ventricles | 8 | 2019 | 1139 | 1.17 | Why? |
| Cardiovascular Diseases | 24 | 2021 | 11497 | 1.17 | Why? |
| RNAi Therapeutics | 3 | 2019 | 35 | 1.13 | Why? |
| Vascular Stiffness | 2 | 2018 | 264 | 1.07 | Why? |
| Pyridines | 2 | 2019 | 680 | 0.98 | Why? |
| Double-Blind Method | 21 | 2019 | 5988 | 0.97 | Why? |
| Ventricular Dysfunction, Left | 7 | 2019 | 993 | 0.93 | Why? |
| Cardiomyopathies | 4 | 2019 | 997 | 0.91 | Why? |
| Troponin T | 5 | 2021 | 771 | 0.89 | Why? |
| Hospitalization | 32 | 2021 | 54280 | 0.85 | Why? |
| Diastole | 3 | 2017 | 168 | 0.83 | Why? |
| Heart Rate | 3 | 2018 | 1527 | 0.82 | Why? |
| Defibrillators, Implantable | 6 | 2019 | 624 | 0.79 | Why? |
| Adenosine A1 Receptor Agonists | 1 | 2018 | 2 | 0.78 | Why? |
| Randomized Controlled Trials as Topic | 12 | 2019 | 10649 | 0.77 | Why? |
| Death, Sudden | 2 | 2018 | 160 | 0.76 | Why? |
| Drug Combinations | 20 | 2019 | 3852 | 0.76 | Why? |
| Echocardiography | 15 | 2020 | 3661 | 0.76 | Why? |
| Insulin-Like Growth Factor Binding Proteins | 1 | 2018 | 35 | 0.75 | Why? |
| Influenza Vaccines | 6 | 2021 | 2941 | 0.74 | Why? |
| Dietary Carbohydrates | 1 | 2018 | 64 | 0.73 | Why? |
| Prognosis | 38 | 2021 | 32490 | 0.73 | Why? |
| Blood Pressure | 6 | 2019 | 2198 | 0.68 | Why? |
| Risk Assessment | 21 | 2021 | 25439 | 0.68 | Why? |
| Clinical Trials, Phase III as Topic | 2 | 2018 | 782 | 0.67 | Why? |
| RNA, Small Interfering | 2 | 2019 | 817 | 0.66 | Why? |
| Influenza, Human | 8 | 2021 | 10779 | 0.66 | Why? |
| Follow-Up Studies | 26 | 2019 | 17020 | 0.66 | Why? |
| Myocardial Contraction | 3 | 2018 | 123 | 0.63 | Why? |
| Aged | 89 | 2021 | 215776 | 0.62 | Why? |
| African Americans | 7 | 2020 | 3363 | 0.61 | Why? |
| Echocardiography, Doppler | 1 | 2017 | 269 | 0.60 | Why? |
| Amyloidosis | 1 | 2017 | 178 | 0.59 | Why? |
| Troponin I | 2 | 2021 | 1298 | 0.58 | Why? |
| Adiposity | 1 | 2018 | 329 | 0.57 | Why? |
| Renin-Angiotensin System | 7 | 2022 | 3661 | 0.56 | Why? |
| Heart Atria | 1 | 2017 | 267 | 0.56 | Why? |
| Male | 104 | 2021 | 367725 | 0.54 | Why? |
| Female | 104 | 2021 | 380317 | 0.54 | Why? |
| Exercise Tolerance | 1 | 2019 | 634 | 0.53 | Why? |
| Treatment Outcome | 38 | 2019 | 51732 | 0.53 | Why? |
| Middle Aged | 84 | 2021 | 270681 | 0.50 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.50 | Why? |
| Heart Arrest | 3 | 2018 | 1239 | 0.49 | Why? |
| Humans | 149 | 2022 | 930598 | 0.49 | Why? |
| Risk Factors | 35 | 2021 | 71621 | 0.47 | Why? |
| Dose-Response Relationship, Drug | 11 | 2019 | 3776 | 0.45 | Why? |
| Delivery, Obstetric | 1 | 2021 | 1292 | 0.45 | Why? |
| Cardiovascular Agents | 4 | 2018 | 663 | 0.45 | Why? |
| Survival Rate | 18 | 2019 | 9206 | 0.45 | Why? |
| Heart Function Tests | 1 | 2012 | 101 | 0.45 | Why? |
| Vascular Diseases | 1 | 2020 | 846 | 0.45 | Why? |
| Cause of Death | 12 | 2019 | 4823 | 0.45 | Why? |
| Hypertension | 6 | 2020 | 8895 | 0.44 | Why? |
| Antihypertensive Agents | 4 | 2019 | 1962 | 0.44 | Why? |
| Death, Sudden, Cardiac | 5 | 2019 | 522 | 0.43 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2017 | 665 | 0.43 | Why? |
| Aged, 80 and over | 31 | 2021 | 88759 | 0.43 | Why? |
| Time Factors | 23 | 2021 | 31397 | 0.43 | Why? |
| Bundle-Branch Block | 4 | 2019 | 127 | 0.41 | Why? |
| Research Design | 4 | 2020 | 5830 | 0.40 | Why? |
| Atrial Fibrillation | 4 | 2018 | 2320 | 0.40 | Why? |
| Malnutrition | 1 | 2019 | 932 | 0.39 | Why? |
| Social Behavior | 1 | 2018 | 882 | 0.39 | Why? |
| Heart Failure, Diastolic | 2 | 2019 | 21 | 0.39 | Why? |
| Cardiotonic Agents | 5 | 2020 | 418 | 0.39 | Why? |
| Biomarkers | 16 | 2021 | 23361 | 0.38 | Why? |
| Heart Diseases | 3 | 2021 | 3503 | 0.37 | Why? |
| Myocardial Infarction | 7 | 2020 | 3361 | 0.37 | Why? |
| Body Mass Index | 3 | 2019 | 4306 | 0.37 | Why? |
| Darbepoetin alfa | 2 | 2018 | 10 | 0.37 | Why? |
| United States | 26 | 2021 | 46150 | 0.37 | Why? |
| International Classification of Diseases | 2 | 2021 | 265 | 0.36 | Why? |
| Fumarates | 5 | 2019 | 38 | 0.36 | Why? |
| Atrial Function, Left | 3 | 2017 | 82 | 0.36 | Why? |
| Angioedema | 2 | 2020 | 111 | 0.36 | Why? |
| Soluble Guanylyl Cyclase | 2 | 2017 | 11 | 0.35 | Why? |
| Heterocyclic Compounds, 2-Ring | 2 | 2017 | 29 | 0.35 | Why? |
| Exercise | 3 | 2019 | 6771 | 0.35 | Why? |
| Prospective Studies | 21 | 2020 | 43301 | 0.34 | Why? |
| Obesity | 6 | 2020 | 7388 | 0.33 | Why? |
| Diabetes Mellitus, Type 2 | 9 | 2019 | 6166 | 0.33 | Why? |
| Hypotension | 3 | 2019 | 392 | 0.32 | Why? |
| Anemia | 3 | 2018 | 789 | 0.31 | Why? |
| Quality of Life | 11 | 2019 | 9820 | 0.31 | Why? |
| Renal Insufficiency, Chronic | 6 | 2020 | 2654 | 0.29 | Why? |
| Diabetes Mellitus | 6 | 2020 | 8207 | 0.28 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.26 | Why? |
| Blood Glucose | 2 | 2018 | 3642 | 0.26 | Why? |
| Stroke | 8 | 2020 | 8839 | 0.26 | Why? |
| Clinical Trials as Topic | 9 | 2020 | 7330 | 0.26 | Why? |
| Diagnostic Imaging | 1 | 2012 | 1044 | 0.25 | Why? |
| Physical Examination | 2 | 2019 | 755 | 0.25 | Why? |
| Diuretics | 3 | 2019 | 326 | 0.25 | Why? |
| Systole | 3 | 2019 | 252 | 0.25 | Why? |
| Up-Regulation | 3 | 2021 | 2249 | 0.24 | Why? |
| Sex Factors | 6 | 2019 | 11014 | 0.24 | Why? |
| Comorbidity | 11 | 2021 | 34796 | 0.22 | Why? |
| Hematinics | 2 | 2018 | 48 | 0.22 | Why? |
| Exocytosis | 1 | 2020 | 34 | 0.22 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.21 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.21 | Why? |
| Proportional Hazards Models | 5 | 2019 | 6543 | 0.21 | Why? |
| Edema, Cardiac | 1 | 2019 | 33 | 0.20 | Why? |
| Cardiology | 3 | 2021 | 2873 | 0.20 | Why? |
| Europe | 9 | 2018 | 12702 | 0.20 | Why? |
| Acute Coronary Syndrome | 3 | 2018 | 2107 | 0.20 | Why? |
| Hyperemia | 1 | 2019 | 62 | 0.20 | Why? |
| Registries | 3 | 2019 | 12327 | 0.19 | Why? |
| Walk Test | 2 | 2019 | 461 | 0.19 | Why? |
| Predictive Value of Tests | 6 | 2021 | 9537 | 0.19 | Why? |
| Biomechanical Phenomena | 2 | 2017 | 291 | 0.19 | Why? |
| P-Selectin | 1 | 2020 | 224 | 0.19 | Why? |
| Incidence | 8 | 2020 | 25622 | 0.19 | Why? |
| Pyrimidines | 2 | 2017 | 1557 | 0.19 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.19 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.18 | Why? |
| Diabetic Neuropathies | 1 | 2018 | 64 | 0.18 | Why? |
| Growth Differentiation Factor 15 | 1 | 2018 | 89 | 0.18 | Why? |
| Digitalis Glycosides | 1 | 2017 | 2 | 0.18 | Why? |
| Fibroblast Growth Factors | 1 | 2019 | 119 | 0.18 | Why? |
| Glucuronidase | 1 | 2019 | 103 | 0.18 | Why? |
| Canrenone | 1 | 2017 | 5 | 0.18 | Why? |
| Heart Failure, Systolic | 1 | 2018 | 39 | 0.18 | Why? |
| Adrenergic beta-Antagonists | 2 | 2018 | 465 | 0.17 | Why? |
| Chagas Cardiomyopathy | 1 | 2017 | 50 | 0.17 | Why? |
| Torsion, Mechanical | 1 | 2017 | 2 | 0.17 | Why? |
| Electrocardiography | 3 | 2018 | 3957 | 0.17 | Why? |
| Phenotype | 3 | 2018 | 4037 | 0.17 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.17 | Why? |
| Cardiac Pacing, Artificial | 1 | 2019 | 160 | 0.17 | Why? |
| Pacemaker, Artificial | 2 | 2019 | 431 | 0.17 | Why? |
| Oligonucleotides, Antisense | 1 | 2018 | 111 | 0.17 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.17 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.17 | Why? |
| Pulse Wave Analysis | 1 | 2018 | 221 | 0.17 | Why? |
| Chi-Square Distribution | 2 | 2017 | 961 | 0.16 | Why? |
| Endothelium | 1 | 2020 | 460 | 0.16 | Why? |
| Renin | 1 | 2017 | 167 | 0.16 | Why? |
| Angiotensins | 1 | 2018 | 259 | 0.16 | Why? |
| Sickle Cell Trait | 1 | 2016 | 59 | 0.16 | Why? |
| North America | 2 | 2018 | 1400 | 0.16 | Why? |
| Amides | 5 | 2019 | 1864 | 0.16 | Why? |
| Hypercholesterolemia | 1 | 2018 | 175 | 0.15 | Why? |
| Benzhydryl Compounds | 1 | 2019 | 240 | 0.15 | Why? |
| Ventricular Fibrillation | 1 | 2017 | 126 | 0.15 | Why? |
| Kaplan-Meier Estimate | 4 | 2018 | 4260 | 0.15 | Why? |
| Echocardiography, Three-Dimensional | 1 | 2017 | 135 | 0.15 | Why? |
| Single-Blind Method | 1 | 2019 | 1283 | 0.15 | Why? |
| Internationality | 2 | 2019 | 3297 | 0.15 | Why? |
| Longevity | 1 | 2017 | 159 | 0.15 | Why? |
| Prediabetic State | 1 | 2017 | 200 | 0.15 | Why? |
| Pulmonary Edema | 1 | 2019 | 430 | 0.14 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.14 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.14 | Why? |
| Nutrition Assessment | 1 | 2019 | 527 | 0.14 | Why? |
| Multicenter Studies as Topic | 2 | 2019 | 2437 | 0.14 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.14 | Why? |
| Patient Reported Outcome Measures | 2 | 2019 | 912 | 0.14 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2017 | 193 | 0.14 | Why? |
| Public-Private Sector Partnerships | 1 | 2018 | 259 | 0.14 | Why? |
| Glucosides | 1 | 2019 | 359 | 0.14 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.14 | Why? |
| Morbidity | 5 | 2019 | 1426 | 0.14 | Why? |
| Uric Acid | 1 | 2017 | 285 | 0.14 | Why? |
| Mortality | 4 | 2019 | 7132 | 0.14 | Why? |
| Reference Values | 1 | 2017 | 795 | 0.14 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.14 | Why? |
| Troponin | 2 | 2018 | 1058 | 0.14 | Why? |
| von Willebrand Factor | 1 | 2020 | 668 | 0.14 | Why? |
| Oxygen Consumption | 1 | 2019 | 711 | 0.14 | Why? |
| Electric Countershock | 1 | 2017 | 284 | 0.13 | Why? |
| Data Interpretation, Statistical | 1 | 2018 | 657 | 0.13 | Why? |
| Diabetic Retinopathy | 1 | 2018 | 347 | 0.13 | Why? |
| Down-Regulation | 1 | 2020 | 1416 | 0.13 | Why? |
| Acute Disease | 4 | 2020 | 6029 | 0.13 | Why? |
| Regression Analysis | 2 | 2018 | 2484 | 0.13 | Why? |
| Disease Progression | 8 | 2019 | 13580 | 0.13 | Why? |
| Argentina | 1 | 2017 | 1141 | 0.12 | Why? |
| Coronary Artery Disease | 2 | 2018 | 2570 | 0.12 | Why? |
| Pneumococcal Vaccines | 1 | 2018 | 571 | 0.12 | Why? |
| Coronary Disease | 1 | 2018 | 645 | 0.11 | Why? |
| Algorithms | 2 | 2019 | 7346 | 0.11 | Why? |
| Hemoglobins | 1 | 2017 | 958 | 0.11 | Why? |
| Terminology as Topic | 1 | 2017 | 546 | 0.11 | Why? |
| Immunization Schedule | 1 | 2019 | 1305 | 0.11 | Why? |
| Adult | 15 | 2021 | 244371 | 0.11 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.11 | Why? |
| Prevalence | 6 | 2020 | 25773 | 0.11 | Why? |
| Pandemics | 14 | 2021 | 389249 | 0.11 | Why? |
| Retrospective Studies | 11 | 2020 | 105322 | 0.11 | Why? |
| Genome-Wide Association Study | 1 | 2018 | 1648 | 0.11 | Why? |
| Intersectoral Collaboration | 1 | 2018 | 1065 | 0.11 | Why? |
| Sweden | 1 | 2017 | 1969 | 0.10 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.10 | Why? |
| Income | 1 | 2019 | 1564 | 0.10 | Why? |
| Ventricular Dysfunction, Right | 1 | 2017 | 639 | 0.10 | Why? |
| Independent Living | 1 | 2016 | 842 | 0.10 | Why? |
| Health Status | 3 | 2019 | 3259 | 0.10 | Why? |
| Myocardium | 2 | 2021 | 2323 | 0.10 | Why? |
| Health Status Disparities | 2 | 2018 | 4072 | 0.10 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.10 | Why? |
| Drug Therapy, Combination | 3 | 2017 | 7268 | 0.09 | Why? |
| Insulin | 1 | 2018 | 1316 | 0.09 | Why? |
| Odds Ratio | 2 | 2019 | 5861 | 0.09 | Why? |
| Uncertainty | 1 | 2020 | 1888 | 0.09 | Why? |
| Frail Elderly | 1 | 2018 | 1427 | 0.09 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.09 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.09 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Cohort Studies | 5 | 2019 | 36005 | 0.09 | Why? |
| Hypoglycemic Agents | 2 | 2018 | 2165 | 0.09 | Why? |
| Cardiac Resynchronization Therapy Devices | 2 | 2018 | 64 | 0.09 | Why? |
| Smoking | 2 | 2019 | 3358 | 0.09 | Why? |
| Least-Squares Analysis | 2 | 2018 | 254 | 0.09 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.09 | Why? |
| Pregnancy Outcome | 1 | 2021 | 3803 | 0.09 | Why? |
| Glomerular Filtration Rate | 3 | 2018 | 1262 | 0.09 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.08 | Why? |
| Canada | 2 | 2017 | 6018 | 0.08 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.08 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.08 | Why? |
| Age Factors | 5 | 2020 | 21039 | 0.08 | Why? |
| Frailty | 1 | 2018 | 1432 | 0.08 | Why? |
| Polyneuropathies | 2 | 2018 | 157 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2019 | 3755 | 0.07 | Why? |
| Societies, Medical | 2 | 2021 | 6907 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Cardiopulmonary Resuscitation | 1 | 2018 | 1876 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Russia | 2 | 2018 | 989 | 0.06 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.06 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Chronic Disease | 4 | 2019 | 5139 | 0.06 | Why? |
| Latin America | 2 | 2018 | 1721 | 0.06 | Why? |
| Adolescent | 5 | 2020 | 86841 | 0.06 | Why? |
| Myocardial Ischemia | 2 | 2019 | 781 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Denmark | 2 | 2020 | 2654 | 0.06 | Why? |
| Machine Learning | 1 | 2018 | 4395 | 0.06 | Why? |
| Patient Admission | 1 | 2019 | 5250 | 0.06 | Why? |
| Case-Control Studies | 2 | 2017 | 17671 | 0.06 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.06 | Why? |
| Patient Discharge | 1 | 2017 | 5696 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2017 | 3222 | 0.05 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Cardiomyopathy, Alcoholic | 1 | 2019 | 6 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2017 | 2324 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Dangerous Behavior | 1 | 2019 | 16 | 0.05 | Why? |
| Brazil | 1 | 2017 | 12582 | 0.05 | Why? |
| Georgia (Republic) | 1 | 2018 | 43 | 0.05 | Why? |
| Europe, Eastern | 1 | 2018 | 88 | 0.05 | Why? |
| Digoxin | 1 | 2018 | 68 | 0.05 | Why? |
| Peripartum Period | 1 | 2019 | 89 | 0.05 | Why? |
| Far East | 1 | 2018 | 125 | 0.05 | Why? |
| Vectorcardiography | 1 | 2018 | 9 | 0.05 | Why? |
| Asia, Western | 1 | 2018 | 271 | 0.05 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.05 | Why? |
| Diabetic Cardiomyopathies | 1 | 2019 | 79 | 0.05 | Why? |
| Precipitating Factors | 1 | 2017 | 31 | 0.04 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.04 | Why? |
| Statistics as Topic | 1 | 2020 | 370 | 0.04 | Why? |
| Sarcomeres | 1 | 2017 | 7 | 0.04 | Why? |
| Gait Disorders, Neurologic | 1 | 2018 | 64 | 0.04 | Why? |
| Los Angeles | 1 | 2020 | 647 | 0.04 | Why? |
| Asia, Southeastern | 1 | 2018 | 390 | 0.04 | Why? |
| Global Health | 5 | 2020 | 13911 | 0.04 | Why? |
| Americas | 1 | 2018 | 418 | 0.04 | Why? |
| Albuminuria | 1 | 2018 | 164 | 0.04 | Why? |
| Face | 1 | 2020 | 301 | 0.04 | Why? |
| Stress, Mechanical | 1 | 2017 | 143 | 0.04 | Why? |
| Hyperkalemia | 1 | 2018 | 140 | 0.04 | Why? |
| Genetic Loci | 1 | 2018 | 439 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| Cardiomyopathy, Dilated | 1 | 2019 | 251 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.04 | Why? |
| Heterozygote | 1 | 2016 | 249 | 0.04 | Why? |
| Peptides | 2 | 2018 | 2513 | 0.04 | Why? |
| Cardiotoxicity | 1 | 2019 | 365 | 0.04 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.04 | Why? |
| Insurance Coverage | 1 | 2019 | 348 | 0.04 | Why? |
| Glomerulonephritis | 1 | 2018 | 226 | 0.04 | Why? |
| Pneumonia, Pneumococcal | 1 | 2018 | 251 | 0.04 | Why? |
| Edema | 1 | 2018 | 333 | 0.04 | Why? |
| Heart Valve Diseases | 1 | 2019 | 355 | 0.03 | Why? |
| Myocardial Revascularization | 1 | 2017 | 267 | 0.03 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.03 | Why? |
| Hypertrophy, Left Ventricular | 1 | 2017 | 219 | 0.03 | Why? |
| Diabetic Nephropathies | 1 | 2018 | 315 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| Insurance, Health | 1 | 2019 | 634 | 0.03 | Why? |
| Tachycardia, Ventricular | 1 | 2017 | 251 | 0.03 | Why? |
| Patients | 1 | 2021 | 1167 | 0.03 | Why? |
| Self Efficacy | 1 | 2019 | 717 | 0.03 | Why? |
| Protective Factors | 1 | 2019 | 1720 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2018 | 552 | 0.03 | Why? |
| Asia | 1 | 2018 | 2399 | 0.03 | Why? |
| Netherlands | 1 | 2020 | 3533 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2017 | 7972 | 0.03 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.03 | Why? |
| Ontario | 1 | 2017 | 1966 | 0.03 | Why? |
| Cardiac Catheterization | 1 | 2018 | 882 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.03 | Why? |
| Indoles | 1 | 2019 | 1243 | 0.03 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.03 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.02 | Why? |
| Drug Industry | 1 | 2017 | 689 | 0.02 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.02 | Why? |
| Ferritins | 1 | 2017 | 2055 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Heart | 1 | 2018 | 1791 | 0.02 | Why? |
| Patient Readmission | 1 | 2017 | 1543 | 0.02 | Why? |
| Alcohol Drinking | 1 | 2019 | 1663 | 0.02 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.02 | Why? |
| Coronary Angiography | 1 | 2017 | 2275 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2017 | 3347 | 0.02 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2018 | 2093 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2019 | 9893 | 0.02 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.02 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2020 | 8495 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.01 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.01 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Virus Diseases | 1 | 2019 | 3779 | 0.01 | Why? |
| Length of Stay | 1 | 2019 | 11042 | 0.01 | Why? |
| Health Behavior | 1 | 2019 | 4449 | 0.01 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Intensive Care Units | 1 | 2019 | 29594 | 0.01 | Why? |
| Lung | 1 | 2019 | 31049 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |